Therapeutic Asset Ratings

151 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Vodudeutentan sodium Cancer	ENB Therapeutics, Inc	P1/2	CC (41)
Vusolimogene Oderparepvec Cancer	Replimune, Inc.	P1/2	CC (41)
XP-102 Cancer	Xynomic Pharmaceuticals, Inc.	P1/2	CC (41)
Zovostotug Cancer	OncoResponse, Inc.	P1/2	CC (41)
azd6244 Cancer	Cancer Research UK	P1	CC (40)
Hmbd-002 Cancer	Hummingbird Bioscience	P1	CC (40)
Mbf-362 Cancer	Medibiofarma S.L.	P1	CC (40)
agx101 Cancer	Angiex, Inc.	P1	C (37)
Allogeneic Nkg2Dl-Targeting Chimeric Antigen Receptor-Grafted Γδ T Cells Cancer	CytoMed Therapeutics Pte Ltd	P1	C (37)
Alta2618 Cancer	Alterome Therapeutics, Inc.	P1	C (37)
Alta3263 Cancer	Alterome Therapeutics, Inc.	P1	C (37)
Bnd-35 Cancer	Biond Biologics	P1	C (37)
cpo301 Cancer	Conjupro Biotherapeutics, Inc.	P1	C (37)
Dfp-14927 Cancer	Delta-Fly Pharma, Inc.	P1	C (37)
dk210 Cancer	DEKA Biosciences	P1	C (37)
Dxp-106 Cancer	Singlomics Biopharmaceuticals Zhuhai Co., Ltd.	P1	C (37)
Enoblituzumab Cancer	Masonic Cancer Center, University of Minnesota	P1	C (37)
GILORALIMAB Cancer	AbbVie	P1	C (37)
Hbi-2376 Cancer	HUYABIO International, LLC.	P1	C (37)
Hbi-2438 Cancer	HUYABIO International, LLC.	P1	C (37)
Icovamenib Cancer	Biomea Fusion Inc.	P1	C (37)
im-1617 Cancer	Immunome, Inc.	P1	C (37)
Inomax Cancer	Beyond Air Inc.	P1	C (37)
Inv-1120 Cancer	Shenzhen Ionova Life Sciences Co., Ltd.	P1	C (37)
jmt108 Cancer	Conjupro Biotherapeutics, Inc.	P1	C (37)

Showing 101 to 125 of 151 assets